188 related articles for article (PubMed ID: 34220851)
1. Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Naïve Versus Effector CD8
Spinelli L; Marchingo JM; Nomura A; Damasio MP; Cantrell DA
Front Immunol; 2021; 12():691997. PubMed ID: 34220851
[TBL] [Abstract][Full Text] [Related]
2. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
Front Immunol; 2018; 9():332. PubMed ID: 29535720
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4
Luff DH; Wojdyla K; Oxley D; Chessa T; Hudson K; Hawkins PT; Stephens LR; Barry ST; Okkenhaug K
Front Immunol; 2021; 12():631271. PubMed ID: 33763075
[TBL] [Abstract][Full Text] [Related]
4. PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.
Dong S; Harrington BK; Hu EY; Greene JT; Lehman AM; Tran M; Wasmuth RL; Long M; Muthusamy N; Brown JR; Johnson AJ; Byrd JC
J Clin Invest; 2019 Jan; 129(1):122-136. PubMed ID: 30457982
[TBL] [Abstract][Full Text] [Related]
5. Exhaustion of the CD8
Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
Front Immunol; 2018; 9():446. PubMed ID: 29563914
[TBL] [Abstract][Full Text] [Related]
6. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
7. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.
Finlay DK; Rosenzweig E; Sinclair LV; Feijoo-Carnero C; Hukelmann JL; Rolf J; Panteleyev AA; Okkenhaug K; Cantrell DA
J Exp Med; 2012 Dec; 209(13):2441-53. PubMed ID: 23183047
[TBL] [Abstract][Full Text] [Related]
8. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.
Soond DR; Bjørgo E; Moltu K; Dale VQ; Patton DT; Torgersen KM; Galleway F; Twomey B; Clark J; Gaston JS; Taskén K; Bunyard P; Okkenhaug K
Blood; 2010 Mar; 115(11):2203-13. PubMed ID: 20081091
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections.
Gracias DT; Boesteanu AC; Fraietta JA; Hope JL; Carey AJ; Mueller YM; Kawalekar OU; Fike AJ; June CH; Katsikis PD
J Immunol; 2016 Feb; 196(3):1186-98. PubMed ID: 26740110
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism.
Macintyre AN; Finlay D; Preston G; Sinclair LV; Waugh CM; Tamas P; Feijoo C; Okkenhaug K; Cantrell DA
Immunity; 2011 Feb; 34(2):224-36. PubMed ID: 21295499
[TBL] [Abstract][Full Text] [Related]
11. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.
Bilancio A; Okkenhaug K; Camps M; Emery JL; Ruckle T; Rommel C; Vanhaesebroeck B
Blood; 2006 Jan; 107(2):642-50. PubMed ID: 16179367
[TBL] [Abstract][Full Text] [Related]
12. The p110delta subunit of phosphoinositide 3-kinase is required for the lipopolysaccharide response of mouse B cells.
Hebeis BJ; Vigorito E; Turner M
Biochem Soc Trans; 2004 Nov; 32(Pt 5):789-91. PubMed ID: 15494016
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p110δ PI3K prevents inflammatory response and restenosis after artery injury.
Bilancio A; Rinaldi B; Oliviero MA; Donniacuo M; Monti MG; Boscaino A; Marino I; Friedman L; Rossi F; Vanhaesebroeck B; Migliaccio A
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28851839
[TBL] [Abstract][Full Text] [Related]
14. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
15. The p110 delta isoform of phosphatidylinositol 3-kinase controls the quality of secondary anti-Leishmania immunity by regulating expansion and effector function of memory T cell subsets.
Liu D; Uzonna JE
J Immunol; 2010 Mar; 184(6):3098-105. PubMed ID: 20154209
[TBL] [Abstract][Full Text] [Related]
16. The phosphoinositide-3-kinase (PI3K)-delta inhibitor seletalisib impairs monocyte-derived dendritic cells maturation, APC function, and promotes their migration to CCR7 and CXCR4 ligands.
Scopelliti F; Mercurio L; Cattani C; Dimartino V; Albanesi C; Costanzo G; Mirisola C; Madonna S; Cavani A
J Leukoc Biol; 2022 Sep; 112(3):383-393. PubMed ID: 35199885
[TBL] [Abstract][Full Text] [Related]
17. Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K.
Okkenhaug K; Ali K; Vanhaesebroeck B
Trends Immunol; 2007 Feb; 28(2):80-7. PubMed ID: 17208518
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio.
Rodríguez-Borlado L; Barber DF; Hernández C; Rodríguez-Marcos MA; Sánchez A; Hirsch E; Wymann M; Martínez-A C; Carrera AC
J Immunol; 2003 May; 170(9):4475-82. PubMed ID: 12707323
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.
Durand CA; Hartvigsen K; Fogelstrand L; Kim S; Iritani S; Vanhaesebroeck B; Witztum JL; Puri KD; Gold MR
J Immunol; 2009 Nov; 183(9):5673-84. PubMed ID: 19843950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
